Top segments and regional performance

Last year, the company generated 0.00 USD, the most of which — ‪1.38 M‬ USD — came from its top-performing segment, Innovative Immunotherapies for Cancer, compared to ‪1.38 M‬ USD the previous year. The greatest contribution came from United States, Germany, United Kingdom and Netherlands, which accounted for ‪1.38 M‬ USD last year, with ‪1.38 M‬ USD the year before.